Bridge Biotherapeutics Presented Preclinical and Phase I Study Results for BBT-401 at the Crohn’s & Colitis Congress
SEONGNAM, South Korea, Feb. 11…
The Art & Science of Wellness
SEONGNAM, South Korea, Feb. 11…
SHENYANG, China and BOSTON, Fe…
Medical imaging’s critic…
BANGKOK, Thailand, Feb. 7, 201…
-New partner ecosystem enables…
SINGAPORE, Feb. 7, 2019 /PRNew…
DARMSTADT, Germany, Feb. 6, 20…
SHENZHEN, China, Feb. 6, 2019 …
多語言WordPress ,採用WPML